Taking together, our results herein demonstrated the synergistic effects of the PARP inhibitors and the SN-38 compound in HR-proficient ovarian cancer cells in vitro and xenograft tumors derived from BRCA1/2-proficient ovarian cancer cells in vivo, which do not respond well to the PARP inhibitors alone. Here, PARP1 is linked to ovarian cancer.